FDA Approves KEYTRUDA QLEX — Merck Sharp & Dohme LLC
Merck is slated to launch KEYTRUDA QLEX, a novel subcutaneous formulation of pembrolizumab, on September 19, 2025, anticipating a shift in market dynamics by potentially reducing infusion times and altering treatment adherence patterns. This innovation strengthens the manufacturer’s portfolio amid intensifying immunotherapy competition and offers a competitive advantage in the growing segment of at-home injectable biologics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day